Business News • PR NewsWire • Efanesoctocog alfa met primary and key secondary endpoints in pivotal study in haemophilia A, demonstrating superiority to prior factor prophylaxis treatment

Efanesoctocog alfa met primary and key secondary endpoints in pivotal study in haemophilia A, demonstrating superiority to prior factor prophylaxis treatment

Efanesoctocog alfa met primary and key secondary endpoints in pivotal study in haemophilia A, demonstrating superiority to prior factor prophylaxis treatment

Once-weekly efanesoctocog alfa met primary endpoint in phase 3 study, resulting in a clinically meaningful prevention of bleeding episodes (bleed protection) In the key secondary endpoint, efanesoctocog alfa demonstrated superiority in prevention of bleeding episodes, showing a...

View More : https://www.prnewswire.com:443/news-releases/efanesoctocog-alfa-met-primary-and-key-secondary-endpoints-in-pivotal-study...

Releted News by prnewswire

SNIPR BIOME announces opening of new BSL2/GMO2-classified laboratory in Copenhagen, Denmark

Kanazawa University research: Changing the handedness of molecules

Intrapartum Monitoring Devices Market to Record 7.5% of Y-O-Y Growth Rate in 2022 | North America Contributes 39% of the Market Growth | Technavio

Efanesoctocog alfa met primary and key secondary endpoints in pivotal study in haemophilia A, demonstrating superiority to prior factor prophylaxis treatment

Expedia reconnaît RateGain comme un partenaire de connectivité privilégié

RateGain wird bevorzugter Konnektivitätspartner von Expedia

Mexico's Finance Minister to Headline LatinFinance Summit In New York Thursday